Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis

Ryan M. Hum, Durga A. Kanigicherla, Pauline Ho

Research output: Contribution to journalArticlepeer-review

Abstract

We present a case of Certolizumab-associated renal sarcoidosis, the first reported case in a patient with psoriatic arthritis (PsA) that was effectively treated with corticosteroids. A 55-year-old Caucasian man with PsA diagnosed age 47, and plaque psoriasis since his early twenties, was on Certolizumab Pegol for 7 months before presenting to the emergency department with seizures and renal failure. A renal biopsy confirmed renal sarcoidosis. His Certolizumab Pegol therapy was stopped, and after several months taking prednisolone at a reducing regime, his renal function improved, and his PsA remained under control. When considering further treatment options for his PsA keeping in mind that other drugs, especially tumour-necrosis-factor-alpha inhibitors (TNFi), have been reported to be associated with sarcoidosis, Tofacitinib was considered to be a future treatment option acceptable to the patient given current NICE guidelines approving its use in PsA, and the lack of reports of Tofacitinib-associated sarcoidosis in the literature.
Original languageEnglish
JournalOxford Medical Case Reports
Publication statusAccepted/In press - 17 Oct 2022

Fingerprint

Dive into the research topics of 'Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis'. Together they form a unique fingerprint.

Cite this